Business Wire

The Estée Lauder Companies Announces Retirement of Alexandra Trower, Executive Vice President, Global Communications

12.4.2021 14:00:00 EEST | Business Wire | Press release

Share

Today, The Estée Lauder Companies (NYSE:EL) (ELC) announced that after 13 years with the company, Alexandra (Alex) Trower, Executive Vice President, Global Communications, will retire effective July 1, 2021. The successor to Alex’s role will be announced at a later date.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005450/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Alex Trower, Executive Vice President, Global Communications, The Estée Lauder Companies, announces retirement. (Photo: Business Wire)

“Alex has been a highly respected thought-leader, collaborative partner, and a trusted senior business advisor,” said Fabrizio Freda, President and CEO, The Estée Lauder Companies. “Leveraging her deep expertise across financial, corporate, consumer and crisis communications, Alex has continuously evolved our strategic communications priorities to drive and support the rapid growth of our business. She built a truly outstanding, global, multi-disciplinary organization and has led her team with wisdom and grace, continuously strengthening the delicate balance of art and science that is ever-present in the world of communications.”

William P. Lauder, Executive Chairman, The Estée Lauder Companies, added: “Against the backdrop of an increasingly complex global landscape, Alex has delivered thoughtful, effective communications to our valued stakeholders, strategically elevating our winning business narrative, rich culture, compelling heritage and distinctive ELC brand equity. She is an outstanding communicator and skilled strategist, and her incredible character, steadfast integrity and deep empathy will be greatly missed across the organization.”

Since joining The Estée Lauder Companies in 2008, Alex has been the architect of ELC’s Global Communications function as it stands today: a highly operationalized, flexible, worldwide and regional structure that prioritizes local relevance, functional expertise and brand-building acumen. Under her leadership, Global Communications has strategically expanded across regions; and through close partnership with regional and affiliate leaders, the department plays a critical role in supporting the company's continued strong regional growth.

Among her many accomplishments, Alex has strategically elevated the company’s reputation worldwide. In 2016, she oversaw the launch of the company’s refreshed Corporate Brand, which represented a transformational change in where, how and why the company engages with its stakeholders. Through this lens, Alex and her team have enabled the organization to communicate boldly, quickly and in more intentional and transparent ways, with an emphasis on strengthening and modernizing the platforms that most resonate with its audiences.

Alex has been a champion of ELC’s efforts across philanthropy, Citizenship and Sustainability, and Inclusion, Diversity and Equity. She serves as a Board member of The Estée Lauder Companies’ Charitable Foundation, is a founding member of the company’s Diversity Council, and served as the first Executive Co-Sponsor of wELCome, the company’s LGBTQA employee resource group.

Mentoring, leading and cultivating talented women is Alex’s passion, which was borne out of her experience as a student at Hollins University, one of the country’s leading women’s universities, where she now serves as the Chair of the Board of Trustees. In 2018, Alex was recognized by New York Women in Communications with a prestigious Matrix Award, presented to her by William P. Lauder in recognition of her exceptional leadership and contributions across the industry. She served as the Co-Chair of the Board of Directors for the International Women’s Media Foundation (IWMF), which supports female journalists worldwide. In 2014, she received the IWMF’s Corporate Leadership Award in recognition of her more than 15 years of service and fundraising.

“I am incredibly proud of all that my team and I have accomplished,” said Alex Trower. “ELC’s Global Communications organization has consistently advanced ahead of the curve, seamlessly partnering with stakeholders across the company and the industry to drive and support the continued success of our business. While the decision to retire is of course bittersweet, I know that the talented Global Communications team is well positioned for its next chapter of growth. On a personal note, it has been an absolute pleasure to serve in this role alongside the Lauder Family and the exceptional ELC executive leadership team.”

About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr. Jart+.

ELC-L
ELC-C

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations:
Rainey Mancini
(212) 284-3049

Media Relations:
Jill Marvin
(212) 572-4438

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye